HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosm… Read more
HPGC Renmintongtai Pharmaceutical Corp (600829) - Total Assets
Latest total assets as of September 2025: CN¥7.02 Billion CNY
Based on the latest financial reports, HPGC Renmintongtai Pharmaceutical Corp (600829) holds total assets worth CN¥7.02 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HPGC Renmintongtai Pharmaceutical Corp - Total Assets Trend (1994–2024)
This chart illustrates how HPGC Renmintongtai Pharmaceutical Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HPGC Renmintongtai Pharmaceutical Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
HPGC Renmintongtai Pharmaceutical Corp's total assets of CN¥7.02 Billion consist of 93.3% current assets and 6.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.4% |
| Accounts Receivable | CN¥4.36 Billion | 60.9% |
| Inventory | CN¥1.10 Billion | 15.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥28.08 Million | 0.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1994–2024)
This chart illustrates how HPGC Renmintongtai Pharmaceutical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HPGC Renmintongtai Pharmaceutical Corp's current assets represent 93.3% of total assets in 2024, an increase from 40.1% in 1994.
- Cash Position: Cash and equivalents constituted 15.4% of total assets in 2024, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 60.9% of total assets.
HPGC Renmintongtai Pharmaceutical Corp Competitors by Total Assets
Key competitors of HPGC Renmintongtai Pharmaceutical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
HPGC Renmintongtai Pharmaceutical Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - HPGC Renmintongtai Pharmaceutical Corp generates 1.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, HPGC Renmintongtai Pharmaceutical Corp generates $ 2.98 in net profit.
HPGC Renmintongtai Pharmaceutical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 1.63 | 1.43 |
| Quick Ratio | 1.40 | 1.36 | 1.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.66 Billion | CN¥ 2.53 Billion | CN¥ 1.67 Billion |
HPGC Renmintongtai Pharmaceutical Corp - Advanced Valuation Insights
This section examines the relationship between HPGC Renmintongtai Pharmaceutical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.07 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -3.5% |
| Total Assets | CN¥7.17 Billion |
| Market Capitalization | $201.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values HPGC Renmintongtai Pharmaceutical Corp's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: HPGC Renmintongtai Pharmaceutical Corp's assets decreased by 3.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for HPGC Renmintongtai Pharmaceutical Corp (1994–2024)
The table below shows the annual total assets of HPGC Renmintongtai Pharmaceutical Corp from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.17 Billion | -3.50% |
| 2023-12-31 | CN¥7.43 Billion | +5.21% |
| 2022-12-31 | CN¥7.06 Billion | +4.60% |
| 2021-12-31 | CN¥6.75 Billion | +12.56% |
| 2020-12-31 | CN¥6.00 Billion | +8.07% |
| 2019-12-31 | CN¥5.55 Billion | +25.72% |
| 2018-12-31 | CN¥4.41 Billion | -8.86% |
| 2017-12-31 | CN¥4.84 Billion | +0.65% |
| 2016-12-31 | CN¥4.81 Billion | +13.65% |
| 2015-12-31 | CN¥4.23 Billion | +28.97% |
| 2014-12-31 | CN¥3.28 Billion | -11.33% |
| 2013-12-31 | CN¥3.70 Billion | -8.65% |
| 2012-12-31 | CN¥4.05 Billion | +5.40% |
| 2011-12-31 | CN¥3.84 Billion | +15.74% |
| 2010-12-31 | CN¥3.32 Billion | +16.38% |
| 2009-12-31 | CN¥2.85 Billion | -2.09% |
| 2008-12-31 | CN¥2.91 Billion | +8.74% |
| 2007-12-31 | CN¥2.68 Billion | +19.69% |
| 2006-12-31 | CN¥2.24 Billion | +12.58% |
| 2005-12-31 | CN¥1.99 Billion | +6.46% |
| 2004-12-31 | CN¥1.87 Billion | +73.51% |
| 2003-12-31 | CN¥1.08 Billion | +15.80% |
| 2002-12-31 | CN¥929.89 Million | -3.21% |
| 2001-12-31 | CN¥960.70 Million | -4.04% |
| 2000-12-31 | CN¥1.00 Billion | +41.06% |
| 1999-12-31 | CN¥709.69 Million | +5.54% |
| 1998-12-31 | CN¥672.44 Million | +0.74% |
| 1997-12-31 | CN¥667.48 Million | +3.28% |
| 1996-12-31 | CN¥646.29 Million | +1.90% |
| 1995-12-31 | CN¥634.21 Million | +4.46% |
| 1994-12-31 | CN¥607.13 Million | -- |